The US still expects to meet its target for delivering COVID-19 vaccines despite Johnson & Johnson struggling with production, a White House senior aide said Monday.

Andy Slavitt, a senior adviser to President Biden’s coronavirus response team, said that the drugmaker is still on track to deliver 24 million doses in April.

“You can expect even without additional doses from Johnson & Johnson for us to be somewhere in that neighborhood,” Slavitt said at a coronavirus press briefing.

That’s not to mention the fact that there are many doses that have already been distributed into states.”

“We are pleased by the fact that Johnson and Johnson in the meantime has taken control of the plant, has eliminated the confounding factor of another vaccine being produced there,” Slavitt said